CAR T Cells Engineered to Target Solid Tumors
Samer A. Srour, MB, ChB, MS, discusses the design of ALLO-316, an agent investigated in the phase 2 TRAVERSE trial for patients with renal cell carcinoma.
Next Steps for Orca-Q in Patients Undergoing Haplo HSCT
Samer A. Srour, MD, MS, discusses what challenges need to be faced when moving forward with the phase 1 trial of Orca-Q in patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.
Allogeneic CAR T-Cell Therapy Shows Safety and Efficacy in RCC
Samer A. Srour, MD, discusses the results of the phase 1 TRAVERSE trial of ALLO-316 in patients with advanced renal cell carcinoma.
Srour Discusses Orca-Q in the Haploidentical Stem Cell Transplant Setting
Samer A. Srour, MD, discusses research on Orca-Q for patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.
Overcoming Challenges With Use of CAR T-Cell Therapy in Solid Tumors
Samer A. Srour, MD, explains the history of researching chimeric antigen receptor T-cell therapy in solid tumors.
Novel Cell Therapy Improves HSCT for Hematologic Malignancies
Samer A. Srour, MD, discusses Orca Q graft and how it’s revolutionized haploidentical allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
Outcomes of Orca-Q in the Haplo SCT Setting for Hematologic Malignancies
Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q.
